Our people

Our team

  • Professor Sir Martin Landray: Martin is the Senior Lead for the Collaborative. He is also CEO of Protas, Professor of Medicine and Epidemiology at the University of Oxford and a consultant hospital physician. Martin has over 20 years’ experience in leading large, randomized trials and is a joint lead of the RECOVERY trial of treatments for Covid-19. He also works closely with regulators, industry, academia, patient groups and government organizations to improve all aspects of clinical trials, and was a lead contributor to the G7 Clinical Trials Charter and the 100 Days Mission for Pandemic Preparedness.
  • Nick Medhurst: Nick is the Team Lead for the Collaborative. He previously worked for patient representative organizations supporting people with breast cancer and cystic fibrosis (CF). He is a board member of CF Europe, a membership organization of patient representative groups, to represent and defend the interest of people with CF.
  • Charlie Rowley: Charlie is the Project Manager for the Collaborative. He previously worked as Project Manager for international non-governmental organizations in the humanitarian sector, focusing on public health and protection.
  • Rachel Hallett: Rachel is the Capacity Strengthening Manager for the Collaborative. She previously held roles in multidisciplinary teams within academia carrying out clinical research and, more recently, developing a Medical Sciences degree programme.
  • Ee Ching Tan: Ee Ching is the Communications Advisor for the Collaborative. She previously worked for a life insurance company based at its Asia headquarters, overseeing the implementation of integrated communications strategies across the region.
  • Stefan Gold: Stefan is the Scientific Advisor to the Collaborative. He is Professor of Clinical Neuroscience and Immunology at Charité Universitätsmedizin Berlin, Germany, with more than 15 years’ experience in conducting investigator-initiated clinical trials in Europe and the US, evaluating both pharmacological and non-pharmacological treatments for neurological and psychiatric diseases. 

Steering group

  • Dr Amrit Ray: Biohaven Pharmaceuticals 
  • Dr Ian Hudson: Bill & Melinda Gates Foundation
  • Jim Elliott: Health Research Authority, UK
  • Dr Dorcas Kamuya: Kenya Medical Research Institute (KEMRI)
  • Professor Kathryn Maitland: Kenya Medical Research Institute (KEMRI)
  • Sir Jeremy Farrar: Wellcome Trust 
  • Mimi Darko: Food and Drug Authority, Ghana
  • Dr Soumya Swaminathan: World Health Organization
  • Professor Sir Martin Landray: Good Clinical Trials Collaborative

Former members

  • Fergus Sweeney: European Medicines Agency 
  • Nancy Roach: Fight Colorectal Cancer 


  • Dr Rob Califf: Food and Drug Administration, USA
  • Janet Woodcock: Food and Drug Administration, USA